发明名称 Fibrinogen immune complexes to diagnose and guide therapy in rheumatoid arthritis
摘要 Compositions and methods are provided for prognostic classification of rheumatoid arthritis disease patients into subtypes, which subtypes are informative of the patient's need for therapy and responsiveness to a therapy of interest.
申请公布号 US9140701(B2) 申请公布日期 2015.09.22
申请号 US201012806081 申请日期 2010.08.04
申请人 THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY 发明人 Robinson William H.;Ho Peggy Pui-Kay;Zhao Xiaoyan;Steinman Lawrence M.
分类号 G01N33/53;G01N33/566;G01N33/564;G01N33/50 主分类号 G01N33/53
代理机构 Bozicevic, Field & Francis LLP 代理人 Bozicevic, Field & Francis LLP ;Sherwood Pamela J.
主权项 1. A method for the prognosis of the severity of rheumatoid arthritis in a human individual, the method comprising: detecting circulating immune complexes containing citrullinated fibrinogen and immunoglobulin in a sample of blood or derivative therefrom obtained from the individual; analyzing the fibrinogen immune complex content in said sample relative to a normal control by contacting the blood sample with C1q protein; contacting immune complexes bound to the C1q protein with an agent that selectively binds to fibrinogen; detecting the presence of a fibrinogen containing immune complexes; wherein the presence of said fibrinogen containing immune complexes, compared to a control sample, is indicative of positive binding; and providing an assessment of prognosis for said individual, where the presence of the immune complexes containing fibrinogen is indicative of a more severe disease prognosis.
地址 Palo Alto CA US